We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
+13.75%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$1.01B
AUM Growth
+$76.5M
(+8.2%)
Cap. Flow
+$73.9M
Cap. Flow
% of AUM
7.34%
Top 10 Holdings %
Top 10 Hldgs %
62.46%
Holding
63
New
12
Increased
4
Reduced
12
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arbutus Biopharma
ABUS
|
+$55.6M |
| 2 |
DVAX
Dynavax Technologies
DVAX
|
+$49.8M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$18.8M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$18.6M |
| 5 |
Omeros
OMER
|
+$17.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$31.1M |
| 2 |
RGLS
Regulus Therapeutics
RGLS
|
+$20.9M |
| 3 |
FWP
Forward Pharma A/S American Depositary Shares
FWP
|
+$20.2M |
| 4 |
Novavax
NVAX
|
+$14.7M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$13.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.3% |
| 2 | Miscellaneous | 18.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Biogen
BIIB
$31.9B
| $1.1M | 0.11% |
2,600
| – | – |
|
|
CELG
52
DELISTED
Celgene Corp
CELG
| $1M | 0.1% |
8,700
| – | – |
|
53
Amgen
AMGN
$203B
| $943K | 0.09% |
5,900
| – | – |
|
54
Acadia Pharmaceuticals
ACAD
$4.61B
| $890K | 0.09% |
27,300
| – | – |
|
|
EIGR
55
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $775K | 0.08% |
91
| – | – |
|
|
KERX
56
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $754K | 0.07% |
59,200
| – | – |
|
57
Puma Biotechnology
PBYI
$477M
| $732K | 0.07% |
3,100
| – | – |
|
|
58
CALL
Acadia Pharmaceuticals
ACAD
$4.61B
| – | – |
-1,000,000
| Closed | -$31.8M |
|
|
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-310,554
| Closed | -$13.9M |
|
|
ACHN
60
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-2,500,000
| Closed | -$30.6M |
|
|
FWP
61
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| – | – |
-138,657
| Closed | -$20.2M |
|
|
KYTH
62
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| – | – |
-22,750
| Closed | -$789K |
|
|
CTIC
63
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| – | – |
-250,000
| Closed | -$5.9M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, RA Capital Management held 63 positions worth $1.01B, up 8.2% from $930M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
RA Capital Management deployed $73.9M of net new capital in Q1 2015, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was Arbutus Biopharma: 2,714,800 shares worth $47.4M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 73% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was bluebird bio, an estimated $31.1M trimmed.
- RA Capital Management's largest Q1 2015 buy was Arbutus Biopharma: 2,714,800 shares worth $47.4M.
- RA Capital Management added most to Achillion Pharmaceuticals in Q1 2015, an estimated $18.8M increase.
- RA Capital Management's biggest Q1 2015 reduction was bluebird bio, cutting an estimated $31.1M.
- RA Capital Management fully exited Forward Pharma A/S American Depositary Shares in Q1 2015, selling an estimated $20.2M.
- RA Capital Management's ten largest holdings make up 62% of its $1.01B portfolio in Q1 2015.
- RA Capital Management opened 12 new positions and closed 6 in Q1 2015.
- RA Capital Management's portfolio value rose 8.2% quarter-over-quarter to $1.01B.
Based on RA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.